The Radiopharmaceutical Theranostics market is experiencing rapid growth due to the increasing demand for precision medicine and targeted oncology therapies. A critical factor driving market expansion is the choice of radioisotope, which determines both the diagnostic and therapeutic efficacy of radiopharmaceutical products. The market is projected to grow from US$ 1,814.58 million in 2022 to US$ 3,441.97 million by 2028, with a CAGR of 11.3% during 2022–2028, highlighting the increasing clinical and commercial importance of radioisotope-based theranostics.

Radioisotopes are central to theranostic applications because they serve dual purposes: enabling high-resolution imaging for diagnosis and delivering targeted radiation therapy to diseased cells. Each isotope offers unique physical and chemical properties, which influence its suitability for specific therapeutic and diagnostic applications.

1. Technetium-99 (Tc-99)

Technetium-99 (Tc-99) is one of the most widely used radioisotopes in nuclear medicine, primarily for diagnostic purposes. With a favorable half-life of six hours and gamma-ray emission properties, Tc-99 allows for high-quality imaging with minimal radiation exposure.

Applications

• Widely used in SPECT imaging for cardiac, skeletal, and renal diagnostics.

• Supports companion diagnostics in oncology by helping locate tumor sites before therapy administration.

Market Drivers

• Established clinical usage with extensive safety and efficacy data.

• Integration with diagnostic imaging systems, enhancing workflow efficiency.

• Continued demand in hospitals and diagnostic centers globally.

While Tc-99 is primarily a diagnostic isotope, its reliability and widespread adoption make it a critical component of the theranostics value chain.

2. Gallium-68 (Ga-68)

Gallium-68 (Ga-68) has gained popularity as a PET tracer, particularly in imaging neuroendocrine tumors (NETs) and prostate cancers. Its short half-life (68 minutes) makes it suitable for same-day imaging, enhancing clinical efficiency.

Applications

• PET imaging for neuroendocrine tumors and prostate-specific membrane antigen (PSMA)-positive cancers.

• Companion diagnostics for patient stratification prior to targeted therapy.

Market Drivers

• Increasing adoption in PET imaging centers due to high sensitivity and resolution.

• Growing demand for precision medicine and personalized oncology treatments.

• Availability of Ga-68 generators, reducing reliance on cyclotrons and enhancing accessibility.

Companies such as Telix Pharmaceuticals Ltd. and GE HealthCare Technologies Inc. are investing heavily in Ga-68 tracers to expand their theranostic product portfolios.

3. Iodine Isotopes (I-131 & I-123)

Iodine isotopes have long-standing applications in both diagnostic imaging and therapy, particularly for thyroid-related diseases.

Iodine-131 (I-131)

• Beta and gamma emitter, making it suitable for both therapy and imaging.

• Widely used in thyroid cancer therapy and hyperthyroidism treatment.

• Supports targeted therapeutic applications in oncology.

Iodine-123 (I-123)

• Pure gamma emitter, ideal for diagnostic imaging.

• Used in SPECT imaging to evaluate thyroid function and detect tumors.

Market Drivers

• Established clinical efficacy and regulatory approvals.

• Integration with hospital nuclear medicine departments ensures steady demand.

• Cost-effectiveness compared to newer isotopes in certain diagnostic procedures.

The combination of I-123 for imaging and I-131 for therapy exemplifies the theranostic approach, enabling clinicians to diagnose and treat patients with high precision.

4. Fluorine-18 (18F)

Fluorine-18 (18F) is a key PET isotope with a half-life of approximately 110 minutes, widely used in oncology imaging and research. Its properties allow for high-resolution PET scans, which are critical for detecting small or early-stage tumors.

Applications

• PET imaging for a wide range of cancers, including lung, brain, and colorectal tumors.

• Companion diagnostics for targeted therapy selection.

Market Drivers

• High adoption in advanced PET imaging centers and oncology hospitals.

• Integration with AI-based imaging analytics enhances diagnostic accuracy.

• Supports personalized medicine by enabling precise tumor localization and therapy monitoring.

GE HealthCare Technologies Inc. and Lantheus Medical Imaging, Inc. are leading developers of 18F-based PET tracers for oncology diagnostics.

5. Yttrium-90 (Y-90)

Yttrium-90 (Y-90) is a high-energy beta emitter primarily used in therapeutic applications, including radioembolization for liver cancer and hematologic malignancies.

Applications

• Targeted therapy for hepatocellular carcinoma using microsphere radioembolization.

• Combination with imaging isotopes for treatment planning and monitoring.

Market Drivers

• Proven therapeutic efficacy in clinical studies.

• Increasing demand for minimally invasive cancer treatments.

• Integration with PET or SPECT imaging for precise dosimetry.

Bayer AG and Curium are key players leveraging Y-90 in theranostic therapies, particularly for oncology applications.

6. Lutetium-177 (Lu-177)

Lutetium-177 (Lu-177) is a cornerstone isotope in the modern theranostics market due to its dual capabilities as a therapeutic beta emitter and gamma emitter for imaging.

Applications

• Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors.

• Targeted therapy for prostate cancer using PSMA-based radioligands.

Market Drivers

• Strong clinical data supporting efficacy in advanced cancers.

• Growing adoption in hospitals, research centers, and oncology clinics.

• Investment from leading companies like Advanced Accelerator Applications S.A. (AAA) and Bayer AG.

Lu-177 is expected to be a key growth driver for the theranostics market, particularly in oncology-focused targeted therapies.

7. Copper Isotopes (Cu-64 & Cu-67)

Copper isotopes are emerging as versatile theranostic agents due to their ability to serve both diagnostic and therapeutic purposes.

Copper-64 (Cu-64)

• PET imaging isotope for detecting and monitoring cancers.

• Suitable for pre-therapy planning and companion diagnostics.

Copper-67 (Cu-67)

• Beta-emitting therapeutic isotope capable of delivering targeted radiation therapy.

• Often paired with Cu-64 for a complete theranostic workflow.

Market Drivers

• Increasing research in novel copper-based radiopharmaceuticals.

• Potential for broader adoption in personalized oncology.

• Ability to combine imaging and therapy within a single isotope system.

Companies like Theragnostics are actively developing copper-based theranostic platforms, highlighting its future potential.

Synergy of Radioisotopes in Theranostics

Radioisotopes in theranostics function as an integrated system:

• Diagnostic isotopes like Tc-99, Ga-68, 18F, and Cu-64 help identify disease sites.

• Therapeutic isotopes like Y-90, Lu-177, I-131, and Cu-67 provide targeted treatment.

• Combined, they enable personalized medicine, precise dosimetry, and monitoring of therapeutic outcomes.

This synergy is central to the growth of the radiopharmaceutical theranostics market and is attracting investment and research attention globally.

Conclusion

The radioisotope segment is a critical determinant of success in the radiopharmaceutical theranostics market. Each isotope—whether Technetium-99, Gallium-68, Iodine-123/131, Fluorine-18, Yttrium-90, Lutetium-177, or Copper-64/67—offers unique clinical advantages for diagnostics, therapy, or both. Key companies, including Bayer AG, GE HealthCare Technologies Inc, Curium, Telix Pharmaceuticals Ltd., Advanced Accelerator Applications S.A., and Thermagnostics, are actively investing in these isotopes to expand their theranostic portfolios.

As the market approaches US$ 3,441.97 million by 2028, radioisotope innovation will continue to drive clinical adoption, personalized oncology solutions, and robust revenue growth. Understanding this segmentation is essential for stakeholders aiming to leverage market opportunities in precision medicine and targeted cancer therapies.

Related Reports

·         Radiopharmaceuticals Market Share and Forecast by 2031

·         Radiopharmaceutical Therapeutic Market Share and Forecast by 2031

·         Specialty Pharmaceuticals Market Report 2031

·         Pharmaceutical Solvent Market Challenges, Key Vendors, Drivers, Trends and Forecast by 2031

·         PET Nuclear Medicine Market Challenges, Key Vendors, Drivers, Trends and Forecast by 2034

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials.

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:

Contact Person: Ankit Mathur

E-mail: ankit.mathur@theinsightpartners.com

Phone: +1-646-491-9876

Also Available in: 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch